Safety check: monitoring liver health in patients taking seizure medication
NCT ID NCT05044819
Summary
This study aims to monitor for potential long-term liver effects in people taking Epidiolex (cannabidiol) for severe seizure disorders. Researchers will follow 154 participants who are either already taking Epidiolex or starting it for FDA-approved conditions. The main goal is to check for signs of liver scarring or injury through specialized tests over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LENNOX GASTAUT SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Clinical Trial Site
Little Rock, Arkansas, 72758, United States
-
Clinical Trial Site
Downey, California, 90242, United States
-
Clinical Trial Site
Long Beach, California, 90806, United States
-
Clinical Trial Site
Sacramento, California, 95817, United States
-
Clinical Trial Site
Miami, Florida, 33136, United States
-
Clinical Trial Site
Miami, Florida, 33176, United States
-
Clinical Trial Site
Orlando, Florida, 32806, United States
-
Clinical Trial Site
Tampa, Florida, 33606, United States
-
Clinical Trial Site
Augusta, Georgia, 30912, United States
-
Clinical Trial Site
Wichita, Kansas, 67214, United States
-
Clinical Trial Site
Lexington, Kentucky, 40504, United States
-
Clinical Trial Site
Baltimore, Maryland, 21205, United States
-
Clinical Trial Site
Boston, Massachusetts, 02114, United States
-
Clinical Trial Site
New Brunswick, New Jersey, 08901, United States
-
Clinical Trial Site
New York, New York, 10016, United States
-
Clinical Trial Site
Charlotte, North Carolina, 28203, United States
-
Clinical Trial Site
Durham, North Carolina, 27708, United States
-
Clinical Trial Site
Cincinnati, Ohio, 45219, United States
-
Clinical Trial Site
Oklahoma City, Oklahoma, 73104, United States
-
Clinical Trial Site
Philadelphia, Pennsylvania, 19107, United States
-
Clinical Trial Site
Charleston, South Carolina, 29425, United States
-
Clinical Trial Site
Austin, Texas, 78758, United States
-
Clinical Trial Site
Dallas, Texas, 75251, United States
-
Clinical Trial Site
Houston, Texas, 77030, United States
-
Clinical Trial Site
Round Rock, Texas, 78681, United States
-
Clinical Trial Site
Winchester, Virginia, 22601, United States
Conditions
Explore the condition pages connected to this study.